secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022593
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q3 loss of $91.7M; China roxadustat revenue up 29% YoY to $17.4M
-------------------------------------------------------------------------

- Total revenue $15.7M vs $156.0M in Q3 2021, which included $120M Astellas milestone
- Net loss $91.7M ($0.98/sh) vs net income $49.8M ($0.54/sh) year ago
- China roxadustat net sales $59.0M (incl. JDE); volume growth >80% vs Q3 2021
- Completed MATTERHORN Phase 3 enrollment; topline data expected 1H 2023
- Non-dilutive royalty monetization with NovaQuest provides $50M; cash target $380-410M YE 2022

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/0000950170-22-022593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/fgen-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer